Guardant Health v. University of Washington
Panel: Moore, Hughes, Stoll
Guardant Health, Inc. v. University of Washington concerns the Federal Circuit's reversal of a PTAB final written decision that found claims 1–30 of U.S. Patent No. 10,760,127 not unpatentable under § 103. The patent relates to duplex consensus sequencing methods for reducing error rates in massively parallel DNA sequencing. The central issue on appeal was whether the Board erred in requiring Guardant to prove a motivation to combine and reasonable expectation of success for performing amplification followed by sequencing when a single prior art reference, Travers '075, expressly disclosed both steps in sequence in a single embodiment (paragraph 122).
The court held that the Board erred by imposing a motivation-to-combine requirement where the disputed claim elements—amplification and sequencing—were disclosed together in the proper sequence within a single embodiment of a single reference. Relying on General Electric Co. v. Raytheon Technologies Corp., the court reasoned that requiring a motivation to combine elements already present together in a reference "unduly dissects prior art references into collections of individual elements" and forces petitioners to "re-do the work already done in the prior art reference." The court rejected the patent owner's argument that Guardant had relied on modifying multiple references, finding instead that the petition's primary theory rested on paragraph 122 of Travers '075 alone, despite the petition's lack of clarity in citing additional materials.